Dr. John M. Kaczmar, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 16
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 238
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
SC license 40321 -
Hematology & Oncology Physician
SC license 40321 -
Internal Medicine Physician
PA license MT197543 -
Student in an Organized Health Care Education/Training Program
PA license MT197543
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Musc Medical Center Charleston, SC
Medical groups
- University Medical Associates of the Medical University of South Carol (1,668 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 238
- Services billed
- 952
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 270 | 124 |
| Established patient office or other outpatient visit, 40-54 minutes | 215 | 73 |
| New patient office or other outpatient visit, 60-74 minutes | 42 | 42 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 18 | 12 |
| Established patient office or other outpatient visit, 20-29 minutes | 18 | 17 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 14 | 11 |
| New patient office or other outpatient visit, 45-59 minutes | 13 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prochlorperazine Maleate Other prescribers in Charleston, SC | 89 |
| Ondansetron Hcl Other prescribers in Charleston, SC | 81 |
| Levothyroxine Sodium Other prescribers in Charleston, SC | 50 |
| Oxycodone Hcl Other prescribers in Charleston, SC | 42 |
| Prednisone Other prescribers in Charleston, SC | 40 |
| Gabapentin Other prescribers in Charleston, SC | 23 |
| Lenvima (lenvatinib mesylate) | 23 |
| Hydrochlorothiazide Other prescribers in Charleston, SC | 17 |
| Eliquis (apixaban) Other prescribers in Charleston, SC | 14 |
| Duloxetine Hcl Other prescribers in Charleston, SC | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 10 payments worth $3,782 in total to this clinician.
| Regeneron Pharmaceuticals, Inc. | $3,677 |
|---|---|
| Axogen | $71.22 |
| Caris Mpi, Inc. | $34.29 |
| Consulting Fee | $3,235 |
|---|---|
| Food and Beverage | $547 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Regeneron Pharmaceuticals, Inc. Jun 27, 2025 | Consulting Fee LIBTAYO · ONCOLOGY | $2,588 |
| Regeneron Pharmaceuticals, Inc. Jun 27, 2025 | Consulting Fee LIBTAYO · ONCOLOGY | $647 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 10 industry-funded studies in 2025, from 7 companies. The companies reported $2,131,145 in research payments for these studies, mostly to the institutions running them.
- First-in-Human, Phase 1,1b, Open-label, Multicenter Study of Bifunctional EGFR,TGF Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients with EGFR-Driven Advanced Solid Tumors
Merck Sharp & Dohme LLC - TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma
Ascendis Pharma Endocrinology Inc · Terminated · NCT05980598 - Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers
Regeneron Pharmaceuticals, Inc. · Completed · NCT03005782 - A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
Aveo Pharmaceuticals, Inc. · Recruiting · NCT06064877 - A randomized, double-blind, placebo-controlled phase 3 study to evalua
GlaxoSmithKline, LLC. - Head And Neck Cancer Squamous Cell Carcinoma
Aveo Pharmaceuticals, Inc. - A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib …
Merck Sharp & Dohme LLC - A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants with High-risk Locally Advanced Cutaneous Squa…
Merck Sharp & Dohme LLC - Study name not reported
Organon Llc - BNT317-01
BioNTech SE
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.